{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:50:31Z","timestamp":1790383831213,"version":"4.1.0"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Implant-associated spinal infections (IASI) pose challenges for outpatient management due to the need for frequent intravenous antibiotic administration. Dalbavancin has a prolonged half-life and is a practical alternative.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Two cases of IASI were treated with dalbavancin in an outpatient setting over 10\u201312 weeks. One patient received therapeutic drug monitoring (TDM)-guided dosing, while the other was managed with fixed-interval dosing. Dalbavancin plasma concentrations were measured using liquid chromatography-tandem mass spectrometry, and dosing adjustments were guided by pharmacokinetic modeling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In the TDM-guided case, three dalbavancin doses were sufficient to maintain therapeutic plasma concentrations (\u22658 mg\/L), whereas the fixed-interval approach required four doses. Both patients successfully completed therapy without recurrence of the infection during follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>TDM-guided dalbavancin therapy optimized drug exposure and reduced the number of doses compared with fixed-interval dosing, highlighting its potential to optimize treatment. Further research is required to establish standardized therapeutic drug monitoring protocols for the management of IASI.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001386","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T12:04:04Z","timestamp":1758283444000},"page":"697-700","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic Drug Monitoring Versus Fixed-Interval Dosing of Dalbavancin in Implant-Associated Spinal Infections: Grand Round\/A Case Study"],"prefix":"10.1097","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5521-2519","authenticated-orcid":false,"given":"Jeroen P.A.","family":"Houwen","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, University Medical Center Utrecht\/Wilhelmina Children's Hospital, Utrecht, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte S.","family":"Hakkers","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Infectious Diseases, University Medical Center Utrecht, Georgia, Utrecht, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentijn A.","family":"Schweitzer","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Bogn\u00e0r","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, University Medical Center Utrecht\/Wilhelmina Children's Hospital, Utrecht, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha L.","family":"Toren-Wielema","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen, the Netherlands; and"},{"name":"Department of Pharmaceutical Analysis, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dani\u00ebl J.","family":"Touw","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen, the Netherlands; and"},{"name":"Department of Pharmaceutical Analysis, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelia H.M.","family":"de Vries Schultink","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, University Medical Center Utrecht\/Wilhelmina Children's Hospital, Utrecht, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"key":"R1-20251107","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40268-024-00458-6","article-title":"Linezolid-induced thrombocytopenia in patients with renal impairment: a case series, review and dose advice","volume":"24","author":"Laarhuis","year":"2024","journal-title":"Drugs R D"},{"key":"R2-20251107","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2165\/11534440-000000000-00000","article-title":"New lipoglycopeptides a comparative review of dalbavancin, oritavancin and telavancin","volume":"70","author":"Zhanel","year":"2010","journal-title":"Drugs"},{"key":"R3-20251107","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1586\/14787210.2015.995633","article-title":"Dalbavancin (BI-387) for the treatment of complicated skin and skin structure infection","volume":"13","author":"Leuthner","year":"2015","journal-title":"Expert Rev Anti Infect Ther"},{"key":"R4-20251107","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s15010-019-01379-2","article-title":"Dalbavancin as a second-line treatment in methicillin-resistant Staphylococcus aureus prosthetic vascular graft infection","volume":"48","author":"Ciccullo","year":"2020","journal-title":"Infection"},{"key":"R5-20251107","doi-asserted-by":"crossref","first-page":"104835","DOI":"10.1016\/j.idnow.2023.104835","article-title":"Dalbavancin as salvage therapy in difficult-to-treat patients for diabetes-related foot osteomyelitis","volume":"54","author":"Boucher","year":"2024","journal-title":"Infect Dis Now"},{"key":"R6-20251107","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ijid.2023.11.003","article-title":"Comparison of dalbavancin with standard of care in the management of infective endocarditis: efficacy, safety, and cost analysis","volume":"138","author":"Su\u00e1rez","year":"2024","journal-title":"Int J Infect Dis"},{"key":"R7-20251107","doi-asserted-by":"crossref","first-page":"1185602","DOI":"10.3389\/fphar.2023.1185602","article-title":"Dalbavancin as suppressive antibiotic therapy in patients with prosthetic infections: efficacy and safety","volume":"14","author":"Ruiz-Sancho","year":"2023","journal-title":"Front Pharmacol"},{"key":"R8-20251107","doi-asserted-by":"crossref","first-page":"106445","DOI":"10.1016\/j.ijantimicag.2021.106445","article-title":"Usefulness of therapeutic drug monitoring in estimating the duration of dalbavancin optimal target attainment in staphylococcal osteoarticular infections: a proof-of-concept","volume":"58","author":"Cojutti","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"R9-20251107","doi-asserted-by":"crossref","first-page":"996","DOI":"10.3390\/antibiotics11080996","article-title":"Population pharmacokinetic and pharmacodynamic analysis of dalbavancin for long-term treatment of subacute and\/or chronic infectious diseases: the major role of therapeutic drug monitoring","volume":"11","author":"Cojutti","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"R10-20251107","doi-asserted-by":"crossref","first-page":"106960","DOI":"10.1016\/j.ijantimicag.2023.106960","article-title":"Expert opinion on dose regimen and therapeutic drug monitoring for long-term use of dalbavancin: expert review panel","volume":"62","author":"Senneville","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"R11-20251107","doi-asserted-by":"crossref","first-page":"ofy331","DOI":"10.1093\/ofid\/ofy331","article-title":"Dalbavancin for the treatment of osteomyelitis in adult patients: a randomized clinical trial of efficacy and safety","volume":"6","author":"Rappo","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"R12-20251107","doi-asserted-by":"crossref","first-page":"7833","DOI":"10.1128\/AAC.01717-15","article-title":"Impact of glycopeptide resistance in Staphylococcus aureus on the dalbavancin in vivo pharmacodynamic target","volume":"59","author":"Lepak","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"R13-20251107","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3390\/antibiotics10080915","article-title":"Determination of a tentative epidemiological cut-off value (ECOFF) for dalbavancin and Enterococcus faecium","volume":"10","author":"Weber","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"R15-20251107","doi-asserted-by":"crossref","first-page":"e0002324","DOI":"10.1128\/aac.00023-24","article-title":"Proactive therapeutic monitoring of dalbavancin concentrations in the long-term management of chronic osteoarticular\/periprosthetic joint infections","volume":"68","author":"Cattaneo","year":"2024","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001386","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T19:00:30Z","timestamp":1762542030000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001386","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,19]]},"assertion":[{"value":"2025-02-13","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}